These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

346 related items for PubMed ID: 12852770

  • 1. Novel bioactive and stable neurotensin peptide analogues capable of delivering radiopharmaceuticals and molecular beacons to tumors.
    Achilefu S, Srinivasan A, Schmidt MA, Jimenez HN, Bugaj JE, Erion JL.
    J Med Chem; 2003 Jul 17; 46(15):3403-11. PubMed ID: 12852770
    [Abstract] [Full Text] [Related]

  • 2. Novel neurotensin analogues for radioisotope targeting to neurotensin receptor-positive tumors.
    Alshoukr F, Rosant C, Maes V, Abdelhak J, Raguin O, Burg S, Sarda L, Barbet J, Tourwé D, Pelaprat D, Gruaz-Guyon A.
    Bioconjug Chem; 2009 Aug 19; 20(8):1602-10. PubMed ID: 19610615
    [Abstract] [Full Text] [Related]

  • 3. Double-stabilized neurotensin analogues as potential radiopharmaceuticals for NTR-positive tumors.
    García-Garayoa E, Maes V, Bläuenstein P, Blanc A, Hohn A, Tourwé D, Schubiger PA.
    Nucl Med Biol; 2006 May 19; 33(4):495-503. PubMed ID: 16720241
    [Abstract] [Full Text] [Related]

  • 4. Novel 99mTc-labeled neurotensin analogues with optimized biodistribution properties.
    Maes V, Garcia-Garayoa E, Bläuenstein P, Tourwé D.
    J Med Chem; 2006 Mar 09; 49(5):1833-6. PubMed ID: 16509599
    [Abstract] [Full Text] [Related]

  • 5. Stabilised 111In-labelled DTPA- and DOTA-conjugated neurotensin analogues for imaging and therapy of exocrine pancreatic cancer.
    de Visser M, Janssen PJ, Srinivasan A, Reubi JC, Waser B, Erion JL, Schmidt MA, Krenning EP, de Jong M.
    Eur J Nucl Med Mol Imaging; 2003 Aug 09; 30(8):1134-9. PubMed ID: 12768332
    [Abstract] [Full Text] [Related]

  • 6. Synthesis and biological effects of c(Lys-Lys-Pro-Tyr-Ile-Leu-Lys-Lys-Pro-Tyr-Ile-Leu) (JMV2012), a new analogue of neurotensin that crosses the blood-brain barrier.
    Bredeloux P, Cavelier F, Dubuc I, Vivet B, Costentin J, Martinez J.
    J Med Chem; 2008 Mar 27; 51(6):1610-6. PubMed ID: 18321036
    [Abstract] [Full Text] [Related]

  • 7. Five Stabilized 111In-labeled neurotensin analogs in nude mice bearing HT29 tumors.
    Janssen PJ, de Visser M, Verwijnen SM, Bernard BF, Srinivasan A, Erion JL, Breeman WA, Vulto AG, Krenning EP, de Jong M.
    Cancer Biother Radiopharm; 2007 Jun 27; 22(3):374-81. PubMed ID: 17651043
    [Abstract] [Full Text] [Related]

  • 8. Toward stable N4-modified neurotensins for NTS1-receptor-targeted tumor imaging with 99mTc.
    Nock BA, Nikolopoulou A, Reubi JC, Maes V, Conrath P, Tourwé D, Maina T.
    J Med Chem; 2006 Jul 27; 49(15):4767-76. PubMed ID: 16854083
    [Abstract] [Full Text] [Related]

  • 9. In vitro and in vivo comparison of human Escherichia coli heat-stable peptide analogues incorporating the 111In-DOTA group and distinct linker moieties.
    Giblin MF, Gali H, Sieckman GL, Owen NK, Hoffman TJ, Forte LR, Volkert WA.
    Bioconjug Chem; 2004 Jul 27; 15(4):872-80. PubMed ID: 15264876
    [Abstract] [Full Text] [Related]

  • 10. Design and in vitro evaluation of branched peptide conjugates: turning nonspecific cytotoxic drugs into tumor-selective agents.
    Falciani C, Brunetti J, Pagliuca C, Menichetti S, Vitellozzi L, Lelli B, Pini A, Bracci L.
    ChemMedChem; 2010 Apr 06; 5(4):567-74. PubMed ID: 20222099
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Novel DOTA-neurotensin analogues for 111In scintigraphy and 68Ga PET imaging of neurotensin receptor-positive tumors.
    Alshoukr F, Prignon A, Brans L, Jallane A, Mendes S, Talbot JN, Tourwé D, Barbet J, Gruaz-Guyon A.
    Bioconjug Chem; 2011 Jul 20; 22(7):1374-85. PubMed ID: 21662976
    [Abstract] [Full Text] [Related]

  • 13. Facile Preparation of a Thiol-Reactive (18)F-Labeling Agent and Synthesis of (18)F-DEG-VS-NT for PET Imaging of a Neurotensin Receptor-Positive Tumor.
    Wu Z, Li L, Liu S, Yakushijin F, Yakushijin K, Horne D, Conti PS, Li Z, Kandeel F, Shively JE.
    J Nucl Med; 2014 Jul 20; 55(7):1178-84. PubMed ID: 24854793
    [Abstract] [Full Text] [Related]

  • 14. Evaluation of the human melanoma targeting properties of radiolabeled alpha-melanocyte stimulating hormone peptide analogues.
    Miao Y, Whitener D, Feng W, Owen NK, Chen J, Quinn TP.
    Bioconjug Chem; 2003 Jul 20; 14(6):1177-84. PubMed ID: 14624632
    [Abstract] [Full Text] [Related]

  • 15. In vivo and in vitro structure-activity studies with peptide and pseudopeptide neurotensin analogs suggest the existence of distinct central neurotensin receptor subtypes.
    Labbé-Jullié C, Dubuc I, Brouard A, Doulut S, Bourdel E, Pelaprat D, Mazella J, Martinez J, Rostène W, Costentin J.
    J Pharmacol Exp Ther; 1994 Jan 20; 268(1):328-36. PubMed ID: 8301574
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Preclinical evaluation of a new, stabilized neurotensin(8--13) pseudopeptide radiolabeled with (99m)tc.
    García-Garayoa E, Bläuenstein P, Bruehlmeier M, Blanc A, Iterbeke K, Conrath P, Tourwé D, Schubiger PA.
    J Nucl Med; 2002 Mar 20; 43(3):374-83. PubMed ID: 11884498
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Antitumor effects and normal tissue toxicity of 111In-labeled epidermal growth factor administered to athymic mice bearing epidermal growth factor receptor-positive human breast cancer xenografts.
    Chen P, Cameron R, Wang J, Vallis KA, Reilly RM.
    J Nucl Med; 2003 Sep 20; 44(9):1469-78. PubMed ID: 12960194
    [Abstract] [Full Text] [Related]

  • 20. New neurotensin analogue radiolabeled by 99m-technetium as a potential agent for tumor identification.
    Emrarian I, Sadeghzadeh N, Abedi SM, Abediankenari S.
    Chem Biol Drug Des; 2018 Jan 20; 91(1):304-313. PubMed ID: 28816013
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.